Trending Stock News

Recro Pharma, Inc. (REPH) Reaches $12.34 After 8.00% Down Move; Last Week Orexigen Therapeutics, Inc. (OREX) Analysts

Orexigen Therapeutics, Inc. (NASDAQ:OREX) Logo

The stock of Recro Pharma, Inc. (NASDAQ:REPH) is a huge mover today! The stock decreased 3.06% or $0.39 during the last trading session, reaching $12.34. About 543,144 shares traded or 105.42% up from the average. Recro Pharma, Inc. (NASDAQ:REPH) has risen 37.47% since May 23, 2017 and is uptrending. It has outperformed by 25.92% the S&P500.The move comes after 5 months negative chart setup for the $253.06M company. It was reported on May, 23 by Barchart.com. We have $11.35 PT which if reached, will make NASDAQ:REPH worth $20.25 million less.

Among 5 analysts covering Orexigen Therapeutics (NASDAQ:OREX), 2 have Buy rating, 2 Sell and 1 Hold. Therefore 40% are positive. Orexigen Therapeutics had 13 analyst reports since August 5, 2015 according to SRatingsIntel. On Saturday, August 8 the stock rating was maintained by Piper Jaffray with “Buy”. Piper Jaffray maintained Orexigen Therapeutics, Inc. (NASDAQ:OREX) rating on Tuesday, October 6. Piper Jaffray has “Overweight” rating and $11 target. RBC Capital Markets upgraded it to “” rating and $9 target in Tuesday, September 15 report. Zacks upgraded the shares of OREX in report on Wednesday, August 5 to “Sell” rating. The company was downgraded on Tuesday, March 13 by Wells Fargo. Bank of America reinitiated Orexigen Therapeutics, Inc. (NASDAQ:OREX) on Friday, December 11 with “Underperform” rating. The stock has “Buy” rating by JP Morgan on Monday, August 10. JMP Securities downgraded Orexigen Therapeutics, Inc. (NASDAQ:OREX) on Wednesday, March 16 to “Market Perform” rating. The company was downgraded on Friday, December 4 by Wells Fargo. On Friday, November 6 the stock rating was maintained by RBC Capital Markets with “Outperform”. See Orexigen Therapeutics, Inc. (NASDAQ:OREX) latest ratings:

13/03/2018 Broker: Wells Fargo Rating: Sell Downgrade

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. The company has market cap of $4.21 million. It offers Contrave for the treatment of obesity. It currently has negative earnings. The firm also offers Contrave under the Mysimba brand name.

The stock decreased 34.42% or $0.117 during the last trading session, reaching $0.2229. About 3.74 million shares traded or 106.55% up from the average. Orexigen Therapeutics, Inc. (NASDAQ:OREX) has declined 95.40% since May 23, 2017 and is downtrending. It has underperformed by 106.95% the S&P500.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $253.06 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

Among 10 analysts covering Recro Pharma (NASDAQ:REPH), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Recro Pharma had 18 analyst reports since August 25, 2015 according to SRatingsIntel. The stock of Recro Pharma, Inc. (NASDAQ:REPH) has “Buy” rating given on Tuesday, July 25 by Piper Jaffray. The rating was initiated by Oppenheimer on Tuesday, February 13 with “Buy”. The rating was initiated by TH Capital with “Buy” on Friday, September 16. The company was maintained on Thursday, May 10 by Oppenheimer. The company was upgraded on Tuesday, August 25 by Zacks. H.C. Wainwright initiated Recro Pharma, Inc. (NASDAQ:REPH) on Wednesday, September 2 with “Buy” rating. The rating was maintained by Piper Jaffray on Wednesday, February 28 with “Buy”. The rating was maintained by Roth Capital on Monday, July 31 with “Buy”. The firm earned “Buy” rating on Monday, November 14 by Aegis Capital. Piper Jaffray initiated the shares of REPH in report on Monday, December 19 with “Overweight” rating.

Since December 12, 2017, it had 0 buys, and 7 selling transactions for $3.53 million activity. Another trade for 1,579 shares valued at $13,956 was made by SCP Vitalife Partners (Israel) II – L.P. on Thursday, January 4. $919,128 worth of stock was sold by Broadfin Healthcare Master Fund Ltd on Tuesday, December 12. Another trade for 38,810 shares valued at $344,688 was made by SCP Vitalife Partners II LP on Tuesday, January 2. Berelowitz Michael sold 7,500 shares worth $78,347.

Analysts await Recro Pharma, Inc. (NASDAQ:REPH) to report earnings on August, 9. They expect $-1.72 EPS, down 258.33% or $1.24 from last year’s $-0.48 per share. After $-0.65 actual EPS reported by Recro Pharma, Inc. for the previous quarter, Wall Street now forecasts 164.62% negative EPS growth.

More notable recent Recro Pharma, Inc. (NASDAQ:REPH) news were published by: Globenewswire.com which released: “Recro Pharma Reports First Quarter 2018 Financial Results” on May 09, 2018, also Globenewswire.com with their article: “Recro Pharma Announces Commercial Team Additions” published on May 02, 2018, Seekingalpha.com published: “Key events next week – healthcare” on May 18, 2018. More interesting news about Recro Pharma, Inc. (NASDAQ:REPH) were released by: Benzinga.com and their article: “The Week Ahead In Biotech: PDUFA Dates, IPOs And More” published on May 21, 2018 as well as Seekingalpha.com‘s news article titled: “Recro Pharma’s (REPH) CEO Gerri Henwood on Q1 2018 Results – Earnings Call Transcript” with publication date: May 09, 2018.

Investors sentiment decreased to 1.5 in 2017 Q4. Its down 0.15, from 1.65 in 2017Q3. It turned negative, as 4 investors sold Recro Pharma, Inc. shares while 14 reduced holdings. 7 funds opened positions while 20 raised stakes. 9.57 million shares or 0.59% less from 9.63 million shares in 2017Q3 were reported. New York State Common Retirement Fund accumulated 6,800 shares. Macquarie Group Inc owns 810 shares. Broadfin Ltd Company has invested 3.68% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH). Alyeska Inv Group Inc Inc Lp stated it has 1.01 million shares. Legal & General Group Incorporated Plc invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Granite Point Cap Mngmt L P has 38,000 shares for 0.03% of their portfolio. 10,000 are held by Rothschild Il. Wells Fargo Co Mn holds 52,848 shares or 0% of its portfolio. Ameritas Invest invested in 1,196 shares or 0% of the stock. Manufacturers Life Co The reported 3,582 shares. Bank Of New York Mellon reported 51,864 shares. Jacobs Levy Equity Mgmt has invested 0.01% in Recro Pharma, Inc. (NASDAQ:REPH). California State Teachers Retirement System invested in 21,600 shares. Dimensional Fund Advisors L P owns 126,954 shares. Royal Financial Bank Of Canada reported 0% stake.

Recro Pharma, Inc. (NASDAQ:REPH) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *